Acadia Q4 2025 GAAP revenue $284M; FY25 $1.07B; NUPLAZID $174M, DAYBUE $110M; FY26 guidance $1.22-1.28B

ACADIA PHARMACEUTICALS INC

2025-FY EPS reported $2.30 revenue$1,071,505,000

Q4 2025 GAAP total revenue $284M; non-GAAP adjusted $298M (+16% YoY); FY25 GAAP $1.07B, non-GAAP $1.08B.
GAAP NUPLAZID net sales $174M (includes $20M IRA rebate adjustment); non-GAAP adjusted $189M, up 17% vs Q4 2024.
DAYBUE net sales $110M in Q4 (+13% YoY) and $391M for FY25.
Net income Q4 $274M ($1.60 diluted EPS) including $250M tax benefit; FY net income $391M ($2.30 EPS). Cash & investments $820M.
FY 2026 guidance: total revenue $1.22-1.28B; NUPLAZID $760-790M; DAYBUE $460-490M; R&D $385-410M; SG&A $660-700M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.